Denosumab Improves Bone Mineral Density and Microarchitecture in Rheumatoid Arthritis: Randomized Controlled Trial by HR-pQCT

Overview

Journal J Bone Miner Metab

Specialty Endocrinology

Date 2023 Jul 22

PMID 37480398

Authors

Ko Chiba

Naoki Iwamoto

Kounosuke Watanabe

Kazuteru Shiraishi

Kengo Saito

Naoki Okubo

Atsushi Kawakami

Makoto Osaki

Affiliations

Soon will be listed here.

Abstract

Introduction: This pre-specified exploratory analysis investigated the effect of denosumab on bone mineral density (BMD) and bone microarchitecture in patients with rheumatoid arthritis (RA) treated with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs).

Materials And Methods: In this open-label, parallel-group study, patients were randomly assigned (1:1) to continuous treatment with csDMARDs plus denosumab or continuous treatment with csDMARD therapy alone for 12 months. BMD and bone microarchitecture were measured by dual-energy X-ray absorptiometry (DXA) and high-resolution peripheral quantitative computed tomography (HR-pQCT).

Results: Of 46 patients enrolled in the primary study, 43 were included in the full analysis set. The mean age was 65.3 years, 88.4% were female, and 60.5% had osteoporosis. Areal BMD of the lumbar spine increased from baseline to 6 and 12 months in both groups, but the increase was higher in the csDMARDs plus denosumab group. Areal BMD of the total hip and femoral neck increased from baseline to 6 and 12 months only in the csDMARDs plus denosumab group. Cortical volumetric BMD and cortical thickness of the distal tibia increased in the csDMARDs plus denosumab group at 6 and 12 months but decreased in the csDMARD therapy alone group. Trabecular bone parameters of the distal tibia improved only in the csDMARDs plus denosumab group at 12 months.

Conclusion: Denosumab may be recommended for patients with RA treated with csDMARDs to increase BMD and improve bone microarchitecture.

Citing Articles

[Systemic versus local demineralization in rheumatoid arthritis : Insights into the bone].

Hoffmann T, Pflug C, Schulze W, Pfeil A Z Rheumatol. 2025; 84(2):88-96.

PMID: 39934433 DOI: 10.1007/s00393-025-01624-0.

Individual trabecula segmentation validation in first- and second-generation high-resolution peripheral computed tomography compared to micro-computed tomography in the distal radius and tibia.

Dinescu A, Zhou B, Hu Y, Agarwal S, Shane E, Guo X JBMR Plus. 2024; 8(3):ziae007.

PMID: 38505220 PMC: 10945717. DOI: 10.1093/jbmrpl/ziae007.

References

Haugeberg G, Uhlig T, Falch J, Halse J, Kvien T . Reduced bone mineral density in male rheumatoid arthritis patients: frequencies and associations with demographic and disease variables in ninety-four patients in the Oslo County Rheumatoid Arthritis Register. Arthritis Rheum. 2001; 43(12):2776-84. DOI: 10.1002/1529-0131(200012)43:12<2776::AID-ANR18>3.0.CO;2-N. View

Hauser B, Riches P, Wilson J, Horne A, Ralston S . Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis. Rheumatology (Oxford). 2014; 53(10):1759-66. DOI: 10.1093/rheumatology/keu162. View

Wright N, Lisse J, Walitt B, Eaton C, Chen Z . Arthritis increases the risk for fractures--results from the Women's Health Initiative. J Rheumatol. 2011; 38(8):1680-8. PMC: 3149716. DOI: 10.3899/jrheum.101196. View

Kim D, Cho S, Choi C, Jun J, Kim T, Lee H . Incidence and risk factors of fractures in patients with rheumatoid arthritis: an Asian prospective cohort study. Rheumatol Int. 2016; 36(9):1205-14. DOI: 10.1007/s00296-016-3453-z. View

Wang Y, Hao Y, Deng X, Li G, Geng Y, Zhao J . [Risk factors for bone mineral density changes in patients with rheumatoid arthritis and fracture risk assessment]. Beijing Da Xue Xue Bao Yi Xue Ban. 2015; 47(5):781-6. View

Kanis J, Johnell O, Oden A, Johansson H, McCloskey E . FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008; 19(4):385-97. PMC: 2267485. DOI: 10.1007/s00198-007-0543-5. View

Furuya T, Hosoi T, Saito S, Inoue E, Taniguchi A, Momohara S . Fracture risk assessment and osteoporosis treatment disparities in 3,970 Japanese patients with rheumatoid arthritis. Clin Rheumatol. 2011; 30(8):1105-11. DOI: 10.1007/s10067-011-1748-8. View

Fujimaki H, Nakazawa A, Hirano M, Takeuchi T, Kadowaki A, Kusayama Y . Status of fracture risk assessment and osteoporosis treatment in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2020; 31(5):987-991. DOI: 10.1080/14397595.2020.1847752. View

Ochi K, Inoue E, Furuya T, Ikari K, Toyama Y, Taniguchi A . Ten-year incidences of self-reported non-vertebral fractures in Japanese patients with rheumatoid arthritis: discrepancy between disease activity control and the incidence of non-vertebral fracture. Osteoporos Int. 2014; 26(3):961-8. DOI: 10.1007/s00198-014-2911-2. View

10.

Klose-Jensen R, Tse J, Keller K, Barnabe C, Burghardt A, Finzel S . High-Resolution Peripheral Quantitative Computed Tomography for Bone Evaluation in Inflammatory Rheumatic Disease. Front Med (Lausanne). 2020; 7:337. PMC: 7381125. DOI: 10.3389/fmed.2020.00337. View

11.

Boutroy S, Bouxsein M, Munoz F, Delmas P . In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab. 2005; 90(12):6508-15. DOI: 10.1210/jc.2005-1258. View

12.

Burghardt A, Lee C, Kuo D, Majumdar S, Imboden J, Link T . Quantitative in vivo HR-pQCT imaging of 3D wrist and metacarpophalangeal joint space width in rheumatoid arthritis. Ann Biomed Eng. 2013; 41(12):2553-64. PMC: 3823828. DOI: 10.1007/s10439-013-0871-x. View

13.

Sundh D, Mellstrom D, Nilsson M, Karlsson M, Ohlsson C, Lorentzon M . Increased Cortical Porosity in Older Men With Fracture. J Bone Miner Res. 2015; 30(9):1692-700. DOI: 10.1002/jbmr.2509. View

14.

Sornay-Rendu E, Boutroy S, Munoz F, Delmas P . Alterations of cortical and trabecular architecture are associated with fractures in postmenopausal women, partially independent of decreased BMD measured by DXA: the OFELY study. J Bone Miner Res. 2006; 22(3):425-33. DOI: 10.1359/jbmr.061206. View

15.

Kostenuik P, Nguyen H, McCabe J, Warmington K, Kurahara C, Sun N . Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res. 2008; 24(2):182-95. DOI: 10.1359/jbmr.081112. View

16.

Park J, Lee N, Lee S . Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation. Mol Cells. 2017; 40(10):706-713. PMC: 5682248. DOI: 10.14348/molcells.2017.0225. View

17.

Zaheer S, LeBoff M, Lewiecki E . Denosumab for the treatment of osteoporosis. Expert Opin Drug Metab Toxicol. 2015; 11(3):461-70. PMC: 4480604. DOI: 10.1517/17425255.2015.1000860. View

18.

Cohen S, Dore R, Lane N, Ory P, Peterfy C, Sharp J . Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008; 58(5):1299-309. DOI: 10.1002/art.23417. View

19.

Takeuchi T, Tanaka Y, Ishiguro N, Yamanaka H, Yoneda T, Ohira T . Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre,.... Ann Rheum Dis. 2015; 75(6):983-90. PMC: 4893103. DOI: 10.1136/annrheumdis-2015-208052. View

20.

Takeuchi T, Tanaka Y, Soen S, Yamanaka H, Yoneda T, Tanaka S . Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled.... Ann Rheum Dis. 2019; 78(7):899-907. PMC: 6585575. DOI: 10.1136/annrheumdis-2018-214827. View